Subscribe

Colorectal Cancer

Lonsurf Receives New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer
FDA Approvals, News & Updates, Colorectal Cancer
August 2023, Vol 14, No 4
On August 2, 2023, the FDA approved a new indication for trifluridine and tipiracil (Lonsurf; Taiho Oncology), in combination with bevacizumab (Avastin), for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti–vascular endothelial growth factor biologic therapy; and if RAS wild-type, an anti–epidermal growth factor receptor therapy.
Read Article
ACS Reports Shift in Colorectal Cancer to Advanced Stage and Younger Age at Diagnosis
By Anne Rowe
Colorectal Cancer
April 2023, Vol 14, No 2
A new report released by the American Cancer Society (ACS) shows that the incidence of colorectal cancer is rapidly increasing among younger individuals, and the disease is also being diagnosed at more advanced stages in people of all ages.
Read Article
Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive, Unresectable or Metastatic Colorectal Cancer
FDA Approvals, News & Updates, Colorectal Cancer
February 2023, Vol 14, No 1
On January 19, 2023, the FDA accelerated the approval of tucatinib (Tukysa; Seagen), a Bruton tyrosine kinase inhibitor, in combination with trastuzumab (Herceptin), a HER2/neu receptor agonist, for the treatment of RAS wild-type, HER2-positive, unresectable or metastatic colorectal cancer (CRC) that progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies.
Read Article
Adagrasib Demonstrates Promising Activity in Patients with KRASᴳ¹²ᶜ-Mutated Metastatic Colorectal Cancer
By Phoebe Starr
Colorectal Cancer
February 2022, Vol 13, No 1 Online Only
Adagrasib (MRTX849), an inhibitor of the KRASG12C mutation, showed promising activity as monotherapy and in combination with cetuximab (Erbitux) in patients with metastatic colorectal cancer (CRC) in the phase 1/2 KRYSTAL-1 trial.
Read Article
Pembrolizumab Shows Long-Term Benefits in Metastatic Colorectal Cancer and MSI-H or dMMR
Colorectal Cancer, In the Literature
February 2021, Vol 12, No 1
Chemotherapy is currently the standard of care for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC); however, some patients have disease that is refractory to chemotherapy.
Read Article
Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation
By Wayne Kuznar
ASCO, Colorectal Cancer, Gastrointestinal Cancers
April 2020, Vol 11, No 2

San Francisco, CA—The combination of encorafenib (Braftovi) plus cetuximab (Erbitux), with or without binimetinib (Mektovi), improved the quality of life based on patient-reported assessments better than current standard of care in the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation, according to the BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium.

Read Article
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
By Wayne Kuznar
Colorectal Cancer, Immunotherapy, Solid Tumors, Personalized Medicine
Web Exclusives
San Francisco, CA—The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) provides durable clinical benefit in patients with previously treated DNA mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC).
Read Article
USPSTF Issues New Colorectal Cancer Screening Recommendations
By Jessica Miller
Colorectal Cancer
July 2016, Vol 7, No 6
New recommendations issued by the US Preventive Services Task Force (USPSTF) focus on increasing colorectal cancer screening, which, according to the task force, is “a substantially underused preventive health strategy.” Previous USPSTF guidelines recommended specific screening approaches, including colonoscopy, fecal occult blood testing, or sigmoidoscopy, for adults aged 50 through 75 years.
Read Article

Page 1 of 2

  • 1
  • 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.